Samsung Biologics Secures US$1.24Bn Manufacturing Deal
Samsung Biologics, a global leader in contract development and manufacturing (CDMO), has announced its largest contract with an Asia-based pharmaceutical company.
The US$1.24bn deal is a significant milestone for Samsung Biologics, representing the largest contract signed by a single client in the company's history.
Production for the deal will take place at Samsung Biologics' state-of-the-art biomanufacturing site in Songdo, South Korea and will run through December 2037.
This new agreement brings the company's total contracts for 2024 to over US$3.3bn, further cementing its position as a major player in the biopharmaceutical manufacturing sector.
Strengthening global biopharmaceutical collaboration
John Rim, President and CEO of Samsung Biologics expressed excitement about the new partnership, stating:
"We are pleased to strategically collaborate with the Asia-based pharmaceutical company to bring effective, high-quality biopharmaceuticals to the global market."
John highlighted the significance of this deal, emphasising that it comes at a crucial time for Samsung Biologics as the company expands its biomanufacturing capacity to meet growing demand.
John added, "Leveraging our capabilities and proven expertise, we plan to maintain momentum for further expansion by fostering trusted and sustainable partnerships with potential and existing clients for mutual growth and ultimately help patients with unmet needs."
Expanding capabilities and operational efficiency
Samsung Biologics is well-positioned to meet the increasing demand for biomanufacturing. It is a fully integrated, end-to-end CDMO service provider, offering solutions that cover the entire biopharmaceutical development and manufacturing process.
With the completion of Bio Campus I, including the opening of Plant 4, Samsung Biologics has a total biomanufacturing capacity of 604 kL. Looking to the future, it has begun work on Bio Campus II with the construction of Plant 5, which will add an additional 180 kL of capacity when it becomes operational in April 2025.
Samsung Biologics' continuous investment in cutting-edge technologies, such as an antibody-drug conjugate (ADC) facility, mRNA manufacturing and enhanced aseptic filling capabilities, reflects its commitment to maintaining operational excellence and meeting client needs.
Samsung Biologics has built a reputation as a trusted CDMO partner, collaborating with 17 of the world's top 20 pharmaceutical companies.
Its customer base continues to expand, especially in key regions like Japan, where it plans to open a regional office in Tokyo to strengthen client relationships.
The latest deal highlights Samsung Biologics' ability to secure high-profile contracts while delivering on its promise of on-time, in-full delivery. #
As demand for biopharmaceutical manufacturing grows, Samsung Biologics remains focused on fostering strong, long-term partnerships with new and existing clients.
Looking Ahead: ADC Facility and Plant 5 Expansion
Samsung Biologics is on track to achieve another milestone: the completion of its dedicated ADC facility by the end of the year. The facility will further enhance its capabilities, particularly for complex projects such as the development of multi specifics.
The company's ongoing construction of Plant 5, which will be operational in April 2025, will bring its total manufacturing capacity to 784 kL across its five plants.
The expansion will allow Samsung Biologics to address its clients' biomanufacturing needs better, especially as the demand for innovative therapies continues to rise.
As a fully integrated CDMO, Samsung Biologics continues to demonstrate its leadership in biomanufacturing. With a strong commitment to investing in state-of-the-art facilities and cutting-edge technologies, the company is poised to meet the growing global demand for high-quality biopharmaceutical production.
Through its strategic partnerships and operational expansion, Samsung Biologics is delivering on its current contracts and shaping the biopharmaceutical industry's future.
As the company continues to innovate, its impact on global healthcare will only grow.
Make sure you check out the latest edition of Manufacturing Digital and also sign up to our global conference series - Manufacturing & Mobility LIVE
Manufacturing Digital is a BizClik brand.
